|Day Low/High||7.10 / 7.38|
|52 Wk Low/High||5.13 / 9.57|
Remembering these 'rules of the road' is vital in this highly volatile space.
Here's two 'rules of the road' when investing in this highly volatile space.
The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.